GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Traws Pharma Inc (FRA:0T2) » Definitions » Cyclically Adjusted PB Ratio

Traws Pharma (FRA:0T2) Cyclically Adjusted PB Ratio : 0.00 (As of May. 15, 2024)


View and export this data going back to 2013. Start your Free Trial

What is Traws Pharma Cyclically Adjusted PB Ratio?

As of today (2024-05-15), Traws Pharma's current share price is €0.59. Traws Pharma's Cyclically Adjusted Book per Share for the quarter that ended in Dec. 2023 was €592.93. Traws Pharma's Cyclically Adjusted PB Ratio for today is 0.00.

The historical rank and industry rank for Traws Pharma's Cyclically Adjusted PB Ratio or its related term are showing as below:

During the past years, Traws Pharma's highest Cyclically Adjusted PB Ratio was 0.40. The lowest was 0.10. And the median was 0.20.

FRA:0T2's Cyclically Adjusted PB Ratio is not ranked *
in the Biotechnology industry.
Industry Median: 1.79
* Ranked among companies with meaningful Cyclically Adjusted PB Ratio only.

The Shiller PE Ratio was first used by professor Robert Shiller. He uses E10 for his Shiller PE Ratio calculation. E10 is the average of the inflation adjusted earnings per share of a company over the past 10 years. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PB Ratio. The Cyclically Adjusted Book per Share is the average of the inflation adjusted book value per share of a company over the past 10 years.

Traws Pharma's adjusted book value per share data for the three months ended in Dec. 2023 was €0.466. Add all the adjusted book value per share for the past 10 years together and divide the count will get our Cyclically Adjusted Book per Share, which is €592.93 for the trailing ten years ended in Dec. 2023.

Shiller PE for Stocks: The True Measure of Stock Valuation


Traws Pharma Cyclically Adjusted PB Ratio Historical Data

The historical data trend for Traws Pharma's Cyclically Adjusted PB Ratio can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Traws Pharma Cyclically Adjusted PB Ratio Chart

Traws Pharma Annual Data
Trend Dec14 Dec15 Dec16 Dec17 Dec18 Dec19 Dec20 Dec21 Dec22 Dec23
Cyclically Adjusted PB Ratio
Get a 7-Day Free Trial Premium Member Only Premium Member Only - - 0.40 - -

Traws Pharma Quarterly Data
Mar19 Jun19 Sep19 Dec19 Mar20 Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23
Cyclically Adjusted PB Ratio Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

Competitive Comparison of Traws Pharma's Cyclically Adjusted PB Ratio

For the Biotechnology subindustry, Traws Pharma's Cyclically Adjusted PB Ratio, along with its competitors' market caps and Cyclically Adjusted PB Ratio data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Traws Pharma's Cyclically Adjusted PB Ratio Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Traws Pharma's Cyclically Adjusted PB Ratio distribution charts can be found below:

* The bar in red indicates where Traws Pharma's Cyclically Adjusted PB Ratio falls into.



Traws Pharma Cyclically Adjusted PB Ratio Calculation

Like the Shiller PE Ratio, the Cyclically Adjusted PB Ratio takes the Book Value per Share from the past 10 years, adjusts it for inflation, and then calculates the average. This average is then used for the P/B calculation. Because it considers this 10-year average, it's often referred to as the CAPB Ratio.

The Shiller PE Ratio was first used by professor Robert Shiller to measure the valuation of the overall market. The similar calculation is applied by GuruFocus to calculate the Cyclically Adjusted PB Ratio.

Traws Pharma's Cyclically Adjusted PB Ratio for today is calculated as

Cyclically Adjusted PB Ratio=Share Price/ Cyclically Adjusted Book per Share
=0.59/592.93
=0.00

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

Traws Pharma's Cyclically Adjusted Book per Share for the quarter that ended in Dec. 2023 is calculated as:

For example, Traws Pharma's adjusted Book Value per Share data for the three months ended in Dec. 2023 was:

Adj_Book=Book Value per Share/CPI of Dec. 2023 (Change)*Current CPI (Dec. 2023)
=0.466/129.4194*129.4194
=0.466

Current CPI (Dec. 2023) = 129.4194.

Traws Pharma Quarterly Data

Book Value per Share CPI Adj_Book
201403 4,803.534 99.695 6,235.755
201406 3,708.204 100.560 4,772.434
201409 2,839.108 100.428 3,658.705
201412 1,911.813 99.070 2,497.491
201503 1,125.803 99.621 1,462.549
201506 345.445 100.684 444.036
201509 284.995 100.392 367.400
201512 811.749 99.792 1,052.746
201603 441.544 100.470 568.768
201606 88.916 101.688 113.164
201609 272.437 101.861 346.145
201612 135.619 101.863 172.308
201703 -110.000 102.862 -138.400
201706 -7.880 103.349 -9.868
201709 -132.389 104.136 -164.533
201712 -206.371 104.011 -256.784
201803 -72.377 105.290 -88.964
201806 36.013 106.317 43.839
201809 24.603 106.507 29.896
201812 12.517 105.998 15.283
201903 -3.458 107.251 -4.173
201906 -10.060 108.070 -12.047
201909 -10.037 108.329 -11.991
201912 1.406 108.420 1.678
202003 1.731 108.902 2.057
202006 1.195 108.767 1.422
202009 0.843 109.815 0.993
202012 0.409 109.897 0.482
202103 1.978 111.754 2.291
202106 1.735 114.631 1.959
202109 2.021 115.734 2.260
202112 1.953 117.630 2.149
202203 1.838 121.301 1.961
202206 1.742 125.017 1.803
202209 1.611 125.227 1.665
202212 1.277 125.222 1.320
202303 1.019 127.348 1.036
202306 0.832 128.729 0.836
202309 0.648 129.860 0.646
202312 0.466 129.419 0.466

Add all the adjusted book value per share together and divide the count will get our Cyclically Adjusted Book per Share.

Please note that we use the CPI data of the country/region where the company is headquartered. If the CPI data for that country/region is not available, then we will use the CPI data of the United States as default.


Traws Pharma  (FRA:0T2) Cyclically Adjusted PB Ratio Explanation

Compared with the regular PB Ratio, which works poorly for cyclical businesses, the Cyclically Adjusted PB Ratio smoothed out the fluctuations of book value during business cycles. Therefore it is more accurate in reflecting the valuation of the company.

If a company has consistent business performance, the Cyclically Adjusted PB Ratio should give similar results to regular PB Ratio.


Traws Pharma Cyclically Adjusted PB Ratio Related Terms

Thank you for viewing the detailed overview of Traws Pharma's Cyclically Adjusted PB Ratio provided by GuruFocus.com. Please click on the following links to see related term pages.


Traws Pharma (FRA:0T2) Business Description

Industry
Traded in Other Exchanges
Address
12 Penns Trail, Newtown, PA, USA, 18940
Onconova Therapeutics Inc is a biopharmaceutical company focused on discovering and developing novel products to treat cancer. The company has proprietary targeted anti-cancer agents designed to disrupt specific cellular pathways that are important for cancer cell proliferation. Onconova's novel, proprietary multi-kinase inhibitor ON 123300 is currently in a dose-escalation and expansion Phase 1 trial in China, and an IND has been filed in the U.S. Its product candidate oral rigosertib is currently in a dose-escalation and expansion Phase 1 investigator-initiated study targeting patients with KRAS+ lung adenocarcinoma in combination with nivolumab.

Traws Pharma (FRA:0T2) Headlines

No Headlines